Literature DB >> 32339655

Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.

Hilal A Lashuel1.   

Abstract

Several lines of evidence from neuropathological studies, human genetics, in vitro aggregation studies and cellular and animal models support the hypothesis that aSyn plays a central role in the formation of Lewy pathologies. These are cytoplasmic proteinaceous and lipid-rich inclusions that represent key pathological hallmarks of Parkinson's disease (PD) and other neurodegenerative diseases, collectively referred to as synucleinopathies. For decades, light microscopy and electron microscopy studies of these inclusions have consistently shown that they are rich in filamentous structures that exhibit distinct distribution and organizational patterns depending on where they occur in the brain (e.g., classical brain-stem Lewy bodies (LBs) and cortical LBs) and the type of synucleinopathies. Although the identity of the protein that form these filaments was a subject of debate for decades, the discovery of PD-linked aSyn mutations, the demonstration that LBs are enriched in insoluble forms of aSyn, and the ability of aSyn to form fibrils of similar dimensions have led to convergence on the hypothesis that aSyn fibrils are key components of LBs. In a recent study, Shahmoradian et al used a combination of advanced electron microscopy and immunofluorescence based imaging techniques to investigate the structure, composition, and architecture of LBs from postmortem brain tissues of individuals with PD or other synucleinopathies (Shahmoradian et al., 2019). The paper's main conclusions suggest that "lipid membrane fragments and distorted organelles together with a non-fibrillar form of αSyn are the main structural building blocks for the formation of Lewy pathology". Their proposal that LBs are devoid of aSyn fibrils or that LB formation occurs independently of aSyn fibril formation casts doubts on a substantial body of work that forms the foundation of many of the current basic and translational research programs in academia and industry. In this article, I present a critical analysis of their data and claims in the context of the existing literature In addition, I examine the extent to which their findings and proposed models of the mechanisms of LB formation are consistent with existing data and are supported by other experimental evidence. The results from this analysis caution against overinterpretation of observations from a single report, especially given the limitations of the techniques and experimental approaches used by Shahmoradian et al and for more collaborative and systematic efforts to revisit and characterize LBs and other aSyn pathologies in the brain pathologies at the biochemical, morphological and structural level.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32339655     DOI: 10.1016/j.nbd.2020.104876

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  27 in total

1.  Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.

Authors:  Daniella Balduino Victorino; Mariana Nejm; Marcia Guimarães-Marques; Fulvio Alexandre Scorza; Carla Alessandra Scorza
Journal:  Pharmaceut Med       Date:  2021-01-07

Review 2.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

3.  Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?

Authors:  Ivan A Kuznetsov; Andrey V Kuznetsov
Journal:  Math Biosci       Date:  2021-12-07       Impact factor: 2.144

Review 4.  Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology.

Authors:  Nicholas P Marotta; Virginia M-Y Lee
Journal:  Curr Opin Neurobiol       Date:  2022-02-04       Impact factor: 7.070

Review 5.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

6.  Crowded organelles, lipid accumulation, and abnormal membrane tubulation in cellular models of enhanced α-synuclein membrane interaction.

Authors:  Maria Ericsson; Victoria von Saucken; Andrew J Newman; Lena Doehr; Camilla Hoesch; Tae-Eun Kim; Ulf Dettmer
Journal:  Brain Res       Date:  2021-02-09       Impact factor: 3.252

7.  Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.

Authors:  Florent Laferrière; Xin He; Federica Zinghirino; Evelyne Doudnikoff; Emilie Faggiani; Wassilios G Meissner; Erwan Bezard; Francesca De Giorgi; François Ichas
Journal:  Cells       Date:  2020-10-29       Impact factor: 6.600

8.  Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson's Disease.

Authors:  Ilya A Kadnikov; Ekaterina R Verbovaya; Dmitry N Voronkov; Mikhail V Voronin; Sergei B Seredenin
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

9.  Pronounced α-Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala.

Authors:  Johannes Burtscher; Jean-Christophe Copin; Carmen Sandi; Hilal A Lashuel
Journal:  eNeuro       Date:  2020-08-17

10.  Megadalton-sized Dityrosine Aggregates of α-Synuclein Retain High Degrees of Structural Disorder and Internal Dynamics.

Authors:  Silvia Verzini; Maliha Shah; Francois-Xavier Theillet; Adam Belsom; Jan Bieschke; Erich E Wanker; Juri Rappsilber; Andres Binolfi; Philipp Selenko
Journal:  J Mol Biol       Date:  2020-10-22       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.